http://www.businesswire.com/news/home/20120107005030/en/Bristol-Myers-Squibb-Acquire-Inhibitex
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections, whose primary focus is on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV).
http://www.minyanville.com/sectors/biotech-pharma/articles/bristol-myers-squibb-gilead-sciences-hepatitis/8/2/2012/id/42915#ixzz28YN24x2x
----------------------------------------------------------------------------------------------------
Achillion Deal Looming as Hepatitis Drugs Fail: Real M&A
By Ryan Flinn and Will Robinson on August 29, 2012
Bristol-Myers Squibb Co.
FDA to review re-submitted Bristol-Myers hepatitis C drug
Mar 12, 2015
(Reuters) - U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.
Bristol-Myers on Thursday said the U.S.
A U.S. federal court has invalidated the U.S. patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version. The patent had been due to expire in 2015.
It's unclear whether the ruling will expose Baraclude to immediate generic competition.
In the multibillion-dollar race to bring oral hepatitis C treatments to market, Bristol-Myers Squibb is leapfrogging Gilead Sciences and Johnson & Johnson by filing for approval for daclatasvir with Japan's Pharmaceutical and Medical Devices Agency.
The daclatasvir and asunaprevir combo therapy is the first all-oral treatment to be filed for approval, eliminating side-effect-riddled interferon and ribavirin.
More info about Phase III Daclatasvir and Sofosbuvir and why Bristol-Myers Squibb is the sponsor and not Gilead
Bristol-Myers looks to rival Gilead for the key to conquering the hep C market
January 14, 2014 | By John Carroll
No matter how hard Bristol-Myers Squibb ($BMY) tried to shame Gilead into pursuing studies for a combination of its hep C drug daclatasvir and the newly approved Sovaldi (sofosbuvir), Gilead Sciences ($GILD) wouldn't budge.
The most effective new therapy for hepatitis C -- two pills that could cure nearly every patient treated -- may never see the light of day because the developers of these new medicines, Bristol-Myers Squibb and Gilead Sciences, seem unable to work together. Apparently, profits are more important than best patient care. Best therapy combines Bristol's daclatasvir with Gilead's GS-7977. Each is a single pill administered once a day.
Thanks for the link.
9 of 9 cleared the virus in the first study with GS-7977 and Ribavirin yet only 53% people had a similar response in the 2nd study. (???)
Another interesting aspect I never picked up in the past is just how many companies are competing to come up with new generation HCV treatments: A whopping seven: Gilead, Abbott, Bristol-Myers, Squibb, J&J, Merck and Vertex.
Bristol-Myers Squibb Co. (BMY) (BMY) lost ground in the race to develop a stand-alone hepatitis C pill after the company suspended testing of an experimental drug for the disease that cost it $2.5 billion to buy earlier this year.
The shares fell as much as 5.9 percent in early trading today after Bristol said yesterday it wouldn’t continue to administer the compound, known as BMS-986094, after a patient developed heart failure, what the company called a “serious safety issue” in a statement.
To answer this, one needs to consider what appears to be serious conflict of interest at Sloan-Kettering. Bristol-Myers-Squibb makes chemotherapeutic drugs. According to a DEF 14A SEC filing of March 22, 2006, the Chairman of the Board of Bristol-Myers-Squibb is also a director of the Coca-Cola Company, and Honorary Chairman of Memorial Sloan-Kettering Cancer Center. (http://sec.edgar-online.com/2006/03/22/0001193125-06-060566/Section8.asp).
In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.
Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters.
Recommended
